Key Factors to Watch as da Vinci V Expansion Continues
Intuitive Surgical (ISRG) has reported strong third-quarter financial results for 2024, with revenues totaling $2.04 billion, in line with consensus estimates. The company posted earnings per share (EPS) of $1.56, exceeding market expectations of $1.37. These results were buoyed by strong sales growth in both the U.S. and international markets, along with the ongoing ramp-up of its da Vinci V surgical system (dV5). However, despite this solid performance, challenges lie ahead, particularly as the company navigates a saturated U.S. market, competitive pressures, and questions surrounding the value proposition of the dV5 system.
Strong Revenue Growth but Competitive Challenges Loom
Intuitive Surgical saw robust revenue growth, with U.S. revenues up 17% year-over-year to $1.38 billion. This included a notable 23% increase in system revenues, which reached $265 million. The company’s international (OUS) revenues grew by 17% to $659 million, with system revenues contributing $180 million, reflecting a 10% year-over-year rise. Instrument and accessory (I&A) revenue, a critical component of Intuitive’s business model, grew by 18%, although it slightly missed analyst expectations.
The solid revenue figures were driven in part by the increased placement of da Vinci systems globally. Intuitive placed 110 da Vinci V systems in the U.S. during the quarter, representing a significant jump from the 70 placements in Q2. The company continues to expand internationally, with new regulatory clearances in South Korea and discussions underway in Japan. While these placements reflect the company’s strong market position, questions remain about the long-term value of the dV5 system, which comes at a 30% premium compared to the previous Xi model.
da Vinci V: The Critical Growth Driver
The da Vinci V system has been a focal point of Intuitive Surgical’s growth strategy, but its economic value remains unclear. While initial uptake has been promising, with 180 dV5 systems placed in the first two quarters of its availability (compared to 104 Xi systems), the long-term success of this new model will depend on its ability to demonstrate clear advantages over its predecessor. Analysts remain cautious about whether hospitals will be willing to pay the 30% price premium for the dV5, especially in the face of rising competition from Medtronic and other surgical robotics companies.
In terms of procedures, Intuitive reported an 18% year-over-year increase in total procedures, with U.S. growth at 16% and international growth at 24%. However, the company’s overall installed base has seen a slight increase in unused capacity, particularly outside the U.S., where 42% of system capacity remains idle. This could pose challenges to future revenue growth if demand does not catch up with system installations.
Valuation and Investment Outlook
Despite the company’s strong financial performance, its valuation remains a point of concern. Intuitive is trading at approximately 18 times forward price-to-sales and 74 times forward price-to-earnings, which suggests that the stock is priced for perfection. The market appears to have already baked in expectations for continued growth, leaving little room for error. Any missteps, such as slower-than-expected dV5 adoption or increased competition, could weigh on the stock’s performance.
The company also faces headwinds from potential new entrants in the market. Medtronic is expected to launch its own robotic surgery system in the U.S. by mid-2025, which could put pressure on Intuitive’s market share. Additionally, Chinese competitors are eyeing international markets, adding further uncertainty to Intuitive’s long-term outlook.
Final Thoughts
Intuitive Surgical’s Q3 2024 results reflect a company that continues to deliver solid growth, both in the U.S. and internationally. The ongoing ramp-up of the da Vinci V system, combined with steady procedure growth, positions the company well for the future. However, the high valuation, combined with competitive pressures and questions surrounding the value of the dV5 system, warrants caution. Investors will be closely watching the company’s next earnings report and any developments in its competitive landscape, particularly as Medtronic’s launch looms on the horizon.
For now, Intuitive Surgical remains a leader in the robotic surgery space, but it will need to navigate several challenges to maintain its dominant position.
You might like this article:Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges
